News

US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Business Wire2d
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
GlobalData on MSN2d
FDA approves KalVista’s Ekterly for hereditary angioedema
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
Fierce Pharma2d
KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
Kalkine Media2d
FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista
KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...
Explore more
BioSpace2d
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
US FDA approves KalVista Pharma's swelling disorder drug
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary ...
PharmExec1d
FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema
Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...
Reuters2d
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its ...